Fig. 2

a Model 2 flow diagram. Shaded areas estimate the source of 649 individuals from a commercial benefits program comprising 100,000 members who would be expected to receive treatment for HCV within 14 years. This group would be responsible for the treatment and medical burden to the payer over the subsequent 14 years. b Standard of Care: cure rates and therapeutic endpoint probabilities. “Standard of Care” = interferon-based treatments used prior to November, 2013. c All Oral Therapy: cure rates and therapeutic endpoint probabilities. “All Oral Therapy” = various combinations of sofosbuvir, ledipasvir and ribavirin. d Natural course of disease progression: therapeutic endpoint probabilities. “Natural Course of Disease Progression” = no treatment